至2023年底,復(fù)宏漢霖總資產(chǎn)為99.04億元,歸屬于母公司股東的所有者權(quán)益21.92億元,負(fù)債總額77.11億元。 復(fù)星醫(yī)藥表示,本次交易完成有利于加強(qiáng)復(fù)星醫(yī)藥集團(tuán)與復(fù)宏漢霖的協(xié)同,并可通過(guò)復(fù)星醫(yī)藥
Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (上海復(fù)星醫(yī)藥(集團(tuán))股份有限公司) (600196.SH) reported a net profit
熱評(píng):
圖片
視頻
Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (上海復(fù)星醫(yī)藥(集團(tuán))股份有限公司) (600196.SH) reported a net profit
熱評(píng):
Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (上海復(fù)星醫(yī)藥(集團(tuán))股份有限公司) (600196.SH) reported a net profit
熱評(píng):
Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (上海復(fù)星醫(yī)藥(集團(tuán))股份有限公司) (600196.SH) reported a net profit
熱評(píng):
Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (上海復(fù)星醫(yī)藥(集團(tuán))股份有限公司) (600196.SH) reported a net profit
熱評(píng):
Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (上海復(fù)星醫(yī)藥(集團(tuán))股份有限公司) (600196.SH) reported a net profit
熱評(píng):
Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (上海復(fù)星醫(yī)藥(集團(tuán))股份有限公司) (600196.SH) reported a net profit
熱評(píng):
Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (上海復(fù)星醫(yī)藥(集團(tuán))股份有限公司) (600196.SH) reported a net profit
熱評(píng):
Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (上海復(fù)星醫(yī)藥(集團(tuán))股份有限公司) (600196.SH) reported a net profit
熱評(píng):